Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 7/20 | 1.00 |
| ▸ | CCR1 | P32246 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18844210 | 0.93 | CCR3 (0.88) | CCR3CCR1ALDH1A1MAPTMEN1 | |
| SCHEMBL14454576 | 0.93 | CCR3 (0.87) | CCR3CCR1ALDH1A1MAPTMEN1 | |
| SCHEMBL18840726 | 0.90 | CCR3 (1.00) | CCR3CCR1ALDH1A1MAPTMEN1 | |
| SCHEMBL18840724 | 0.87 | CCR3 (1.00) | CCR3CCR1MAPTMEN1KMT2A | |
| SCHEMBL18840693 | 0.86 | CCR3 (1.00) | CCR3CCR1ALDH1A1MAPTMEN1 | |
| SCHEMBL2213599 | 0.83 | CCR3 (0.71) | CCR3CCR1ALDH1A1MAPTMEN1 | |
| SCHEMBL1812120 | 0.82 | CCR3 (0.69) | CCR3CCR1ALDH1A1MAPTMEN1 | |
| SCHEMBL1812124 | 0.82 | CCR3 (0.69) | CCR3CCR1ALDH1A1MAPTMEN1 | |
| SCHEMBL4034267 | 0.81 | CCR3 (0.84) | CCR3CCR1ALDH1A1MEN1KMT2A | |
| SCHEMBL2212518 | 0.81 | CCR3 (0.70) | CCR3CCR1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155663-A1 | Use of chemokine receptor agonists for stem cell transplantation | TAP PHARMACEUTICAL PRODUCTS INC. | 2007-07-05 | — | — | US | claimed |
| EP-1605966-A1 | USE OF CHEMOKINE RECEPTOR AGONISTS FOR STEM CELL TRANSPLANTATION | TAP Pharmaceutical Products, Inc. (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004084931-A1 | USE OF CHEMOKINE RECEPTOR AGONISTS FOR STEM CELL TRANSPLANTATION | TAP PHARMACEUTICALS PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | claimed |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) | 2019-09-03 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | CCR3, CCR5, CCR1 | CCR3 1/4885CCR1 3/4885ALDH1A1 1318/4885 |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | CCR3, CCR5, CCR1 | CCR3 1/4885CCR1 3/4885ALDH1A1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.